Related Experiment Video
Updated: Dec 8, 2025
Author Spotlight: Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model
Published on: June 9, 2023
Use of vasopressin in neonatal hypertrophic obstructive cardiomyopathy: case series
Stephanie M Boyd1,2, Kristin L Riley3, Regan E Giesinger1,3
1Neonatology Department, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G1X8, Canada.
Insights
Vasopressin administration improved arterial blood pressure in infants with neonatal hypertrophic obstructive cardiomyopathy (HOCM). This treatment also reduced heart rate and oxygen needs, but requires careful monitoring for potential hyponatremia.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Pharmacology
Background:
- Neonatal hypertrophic obstructive cardiomyopathy (HOCM) presents significant hemodynamic challenges.
- Systemic hypotension is a critical concern in affected infants.
- Limited therapeutic options exist for stabilizing hemodynamics in neonatal HOCM.
Purpose of the Study:
- To evaluate the impact of vasopressin on arterial blood pressure in infants diagnosed with neonatal HOCM.
- To assess the effects of vasopressin on other hemodynamic parameters and oxygen requirements.
Main Methods:
- A retrospective case study was conducted in a Neonatal Intensive Care Unit.
- The study involved six infants with neonatal HOCM, five born to mothers with diabetes mellitus.
- Vasopressin infusion was initiated at a mean dose of 0.3 ± 0.2 mU/kg/min.
Main Results:
- Initiation of vasopressin led to significant improvements in mean, systolic, and diastolic arterial pressure within 2 hours (p < 0.05).
- A notable decline in heart rate and oxygen requirement was observed post-vasopressin initiation (p < 0.05).
- Serum sodium levels initially decreased but recovered by 72 hours (p = 0.017).
Conclusions:
- Vasopressin may be beneficial in improving systemic hypotension and stabilizing hemodynamics in neonatal HOCM.
- Potential for hyponatremia necessitates vigilant fluid and electrolyte management.
- Further prospective randomized trials are required to confirm the safety and efficacy of vasopressin in this population.
Objective:
To determine the effect of vasopressin on arterial blood pressure in infants with neonatal hypertrophic obstructive cardiomyopathy (HOCM).
Study Design:
Retrospective case study in Neonatal ICU involving six infants; five born to mothers with diabetes mellitus (mean gestational age 37.5 ± 0.9 weeks). Vasopressin infusion was started at a mean dose of 0.3 ± 0.2 mU/kg/min.
Result:
Initiation of vasopressin was followed by improved mean (p = 0.004), systolic (p = 0.028), and diastolic (p = 0.009) arterial pressure within 2 h. Heart rate (p = 0.025) and oxygen requirement (p = 0.021) also declined after initiation. Serum sodium declined initially and recovered by 72 h (p = 0.017).
Conclusion:
Although there is limited experience with vasopressin use in neonatal HOCM, our case series suggests it may be beneficial for improving systemic hypotension and stabilization of hemodynamics. The potential for hyponatremia is high, necessitating careful fluid/electrolyte management. A prospective randomized trial is necessary to confirm safety and efficacy of vasopressin treatment in neonatal HOCM.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy